Leukemia
ecancer
Epitope Editing Enables Targeted Immunotherapy of AML
FEATURING
Gabriele Casirati
- 12 views
- October 23, 2023
ASH 2022 Conference Coverage
Results From the Phase 3 ALPINE Study: Zanubrutinib vs. Ibrutinib in R/R CLL & SLL
FEATURING
Jennifer Brown
- 185 views
- April 14, 2023
ecancer
ALPINE: A Randomized Phase 3 Study of Zanubrutinib vs. Ibrutinib for Treatment of R/R CLL and SLL
FEATURING
Jennifer Brown
- 492 views
- January 11, 2023
- 1
Dana-Farber Cancer Institute
What's New in AML: Approach to Relapsed and Refractory Disease
FEATURING
Marlise R. Luskin
- 560 views
- September 6, 2019
- 1
Dana-Farber Cancer Institute
FDA Approval of Duvelisib for CLL
FEATURING
Jennifer Brown
- 460 views
- December 20, 2018
- 3
Dana-Farber Cancer Institute
What is Clonal Hematopoiesis and Why Does It Matter?
FEATURING
David P. Steensma
- 2,078 views
- September 26, 2018
- 12
Dana-Farber Cancer Institute
Ask the Experts: How I Treat CLL in 2018 Discussion
FEATURING
Matthew Davids
- 171 views
- September 8, 2018
- 1
Dana-Farber Cancer Institute
Approach to Frontline Treatment of CLL in 2018
FEATURING
Matthew Davids
- 594 views
- September 8, 2018
- 3
Dana-Farber Cancer Institute
CML Frontline Treatment Choice and Monitoring
FEATURING
Daniel J. DeAngelo
- 218 views
- May 7, 2018
Dana-Farber Cancer Institute
Advances in the Use of Monoclonal Antibodies for ALL
FEATURING
Daniel J. DeAngelo
- 148 views
- April 3, 2018
Dana-Farber Cancer Institute
Mapping the Future of Acute Lymphoblastic Leukemia
FEATURING
Daniel J. DeAngelo
- 202 views
- January 8, 2018
- 1
Dana-Farber Cancer Institute
FLT-3 Inhibitors in AML
FEATURING
Richard Stone
- 567 views
- December 27, 2017
- 1